Brain Aging in the Hispanic Community: Why the NIH is Investing $16 Million in Research

If you take 100 adults over 65 in the U.S., what percentage will develop dementia? Among whites: 11%. Among Asians: 9%. Among Latinos: 17%. The difference is dramatic, but the reason is unclear. The NIH believes it's time to solve the puzzle. Consequently, this month a grant of $15.85 million was awarded to UC Davis Health and UC San Diego to follow 1,800 Latino adults for 12 years. This is one of the largest studies in the world on brain aging in this population, and it is now becoming a model for future aging research.

The Problem: Most Aging Research on White Populations

For decades, most major studies on Alzheimer's, Parkinson's, and cognitive decline were conducted on white American or European populations. The reasons:

• Access to research clinics: Latinos in the U.S. are less likely to participate in trials, due to issues of trust, language, insurance, and location
• Recruiter biases: Researchers prefer well-documented populations
• Communication barriers: Survey questionnaires in English only
• History of mistrust: Minority communities remember past abuses (Tuskegee, etc.)

The result: Drugs and diagnostic approaches were developed on one population and applied to everyone, even if the biology is different.

Why Do Latinos Develop Dementia More?

The rates among Latinos are higher for complex reasons:

1. Higher rates of diabetes: 12% vs. 8% among whites. Diabetes is a proven risk factor for dementia
2. Obesity: 45% vs. 35% among whites
3. Limited access to healthcare: 18% uninsured (vs. 8% among whites)
4. Lower average education: Each additional year of education adds brain resilience
5. Mixed Native American genetics: Latinos carry different genetic combinations that may affect aging pathways
6. Chronic socio-economic stress: Many live in polluted environments with constant financial strain

The Trial: 12 Years, 1,800 Participants

The study, led by Prof. Charles DeCarli from UC Davis and Prof. Hector Gonzalez from UC San Diego, will investigate:

• 1,800 Latinos over age 50
• 12 years of follow-up
• Repeated MRI scans (baseline, midpoint, end)
• Blood tests for dementia biomarkers (plaques, tau, synaptic proteins)
• Professional cognitive tests in 2 languages (Spanish and English)
• Collection of information on lifestyle, diet, physical activity, stress
• Genetic tests to identify unique variants

The team will build the world's largest database on brain aging in Latinos, open to other researchers who can use it.

Interesting Aspects to be Examined

The researchers hope to answer unclear questions:

1. Do Alzheimer's drugs work in Latinos? New drugs like lecanemab were developed on white patients. We don't know if they are equally effective
2. What unique genes do Latinos have? There may be unique variants that protect or put at risk
3. How do cultural factors influence? The close-knit family tradition among Latinos can be a shield (social support) or a danger (caregiving stress)
4. Which interventions are most effective? Diet, physical activity, education - what interventions work in this community?

A Model for Future Studies

This is not the first of its kind, but it is the largest. If successful, it will be a model for studying other underrepresented populations:

• African Americans (also at increased risk)
• Asians (lower risk, but with unique characteristics)
• Native Americans (massive underrepresentation)
• Impoverished populations in Europe and Australia

The expectation: In 5-10 years, medicine will not be "one-size-fits-all" but rather medicine tailored to the population and the patient.

Why This is Relevant to Everyone, Even Non-Latinos?

Even if you are not Hispanic, the findings will be relevant:

• Shared genetics: Genes that protect Latinos may also work in others
• Cross-cutting risk factors: Diabetes, obesity, stress - for everyone
• Comparison to other species: Understanding Latino aging helps understand aging in general

How to Participate?

If you are a Latino in the U.S. over 50 and meet the criteria, you can register through the university websites. The team is looking for a variety of regions, ages, and health conditions (both healthy and those with cognitive decline). Participation includes free tests over 12 years. Many hope the study itself will contribute to their health.

Implications for Treatments

If the study reveals that certain drugs work less well in Latinos, pharmaceutical companies will need to develop adapted versions. This will increase costs but improve outcomes. The expectation: Some drugs will go back to the drawing board with tailored genetic corrections.

The Bottom Line

This study is a vital step in the evolution of medicine. We are approaching an era where a "cure for Alzheimer's" will not exist. Instead, there will be different drugs for different populations, based on their genetics and lifestyle. By 2030+, a doctor saying "You are Hispanic, this drug works better for you" will sound normal. But to get there, someone needs to do the work. The NIH and UC are doing it now.